Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21966972 | 0.87 | DRD2 (0.49) | LMNAMAPTKMT2AC5AR1ALDH1A1 | |
| SCHEMBL21968821 | 0.85 | ALDH1A1 (0.46) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12074844 | 0.79 | LMNA (0.52) | LMNAMAPTMEN1KMT2AC5AR1 | |
| SCHEMBL14355821 | 0.77 | MEN1 (0.49) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL25870823 | 0.77 | GAA (0.56) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL12160692 | 0.77 | ALDH1A1 (0.43) | LMNAMAPTMEN1KMT2AATM | |
| SCHEMBL20351350 | 0.77 | ALDH1A1 (0.44) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL18789903 | 0.77 | KMT2A (0.44) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13326993 | 0.77 | MEN1 (0.47) | LMNAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL6166265 | 0.76 | MEN1 (0.45) | LMNAMEN1KMT2AATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660897-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-9573897-B2 | C5AR antagonists | CHEMOCENTRYX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-8906938-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2011163640-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010075257-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-10660897-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20110275639-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2969/4885MAPT 4107/4885MEN1 2647/4885 |
| US-20170065604-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | LMNA 2758/4885MAPT 4239/4885MEN1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.